Obeticholic acid for the treatment of primary biliary cholangitis.
Ali AH, Lindor KD.
Expert Opin Pharmacother · review; journal article · DOI 10.1080/14656566.2016.1218471 PUBLICATION REGISTRY
Go to research.
Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.
Publikationer som ChEBI hänvisar till för obeticholic acid. Visa hela publikationsregistret
A publication hit is not a conclusion. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.
Publications in the selection
25 hitsObeticholic Acid: First Global Approval.
Markham A, Keam SJ.
Drugs · review; journal article · DOI 10.1007/s40265-016-0616-xBile acid receptor agonists INT747 and INT777 decrease oestrogen deficiency-related postmenopausal obesity and hepatic steatosis in mice.
de Oliveira MC, Gilglioni EH, de Boer BA, Runge JH, de Waart DR, Salgueiro CL, Ishii-Iwamoto EL, Oude Elferink RP, Gaemers IC.
Biochim Biophys Acta · journal article · DOI 10.1016/j.bbadis.2016.07.012Cardiopulmonary protective effects of the selective FXR agonist obeticholic acid in the rat model of monocrotaline-induced pulmonary hypertension.
Vignozzi L, Morelli A, Cellai I, Filippi S, Comeglio P, Sarchielli E, Maneschi E, Vannelli GB, Adorini L, Maggi M.
J Steroid Biochem Mol Biol · journal article · DOI 10.1016/j.jsbmb.2016.07.004Effects of obeticholic acid on lipoprotein metabolism in healthy volunteers.
Pencek R, Marmon T, Roth JD, Liberman A, Hooshmand-Rad R, Young MA.
Diabetes Obes Metab · clinical trial, phase i; randomized controlled trial; journal article · DOI 10.1111/dom.12681Obeticholic acid, a synthetic bile acid agonist of the farnesoid X receptor, attenuates experimental autoimmune encephalomyelitis.
Ho PP, Steinman L.
Proc Natl Acad Sci U S A · research support, non-u.s. gov't; research-article; journal article · DOI 10.1073/pnas.1524890113Gene expression profiling in human precision cut liver slices in response to the FXR agonist obeticholic acid.
Ijssennagger N, Janssen AWF, Milona A, Ramos Pittol JM, Hollman DAA, Mokry M, Betzel B, Berends FJ, Janssen IM, van Mil SWC, Kersten S.
J Hepatol · research support, non-u.s. gov't; journal article · DOI 10.1016/j.jhep.2016.01.016Obeticholic acid reduces bacterial translocation and inhibits intestinal inflammation in cirrhotic rats.
Úbeda M, Lario M, Muñoz L, Borrero MJ, Rodríguez-Serrano M, Sánchez-Díaz AM, Del Campo R, Lledó L, Pastor Ó, García-Bermejo L, Díaz D, Álvarez-Mon M, Albillos A.
J Hepatol · research support, non-u.s. gov't; journal article · DOI 10.1016/j.jhep.2015.12.010Obeticholic acid for the treatment of primary biliary cirrhosis.
Trivedi PJ, Hirschfield GM, Gershwin ME.
Expert Rev Clin Pharmacol · review; journal article · DOI 10.1586/17512433.2015.1092381Trials of obeticholic acid for non-alcoholic steatohepatitis.
Musso G, Cassader M, Gambino R.
Lancet · letter; comment · DOI 10.1016/s0140-6736(15)61198-9Trials of obeticholic acid for non-alcoholic steatohepatitis - Authors' reply.
Neuschwander-Tetri BA, Van Natta ML, Tonascia J, Brunt EM, Kleiner DE.
Lancet · letter; comment · DOI 10.1016/s0140-6736(15)61200-4Trials of obeticholic acid for non-alcoholic steatohepatitis.
Armstrong MJ, Newsome PN.
Lancet · letter; comment · DOI 10.1016/s0140-6736(15)61199-0The Appropriate Timing and Dose of Obeticholic Acid in Patients With Primary Biliary Cirrhosis.
Dong R, Zheng S, Chen G.
Gastroenterology · letter; comment · DOI 10.1053/j.gastro.2015.01.050Obeticholic acid: expanding the therapeutic landscape of NASH.
Arrese M, Cabrera D, Barrera F.
Ann Hepatol · research support, non-u.s. gov't; review; journal article · DOI 10.1016/s1665-2681(19)31286-4Obeticholic acid and resveratrol in nonalcoholic fatty liver disease: all that is gold does not glitter, not all those who wander are lost.
Musso G.
Hepatology · journal article · DOI 10.1002/hep.27772Is obeticholic Acid the solution to nonalcoholic steatohepatitis?
Wong VW, Wong GL, Chan FK.
Gastroenterology · comment; journal article · DOI 10.1053/j.gastro.2015.02.044The FXR agonist obeticholic acid prevents gut barrier dysfunction and bacterial translocation in cholestatic rats.
Verbeke L, Farre R, Verbinnen B, Covens K, Vanuytsel T, Verhaegen J, Komuta M, Roskams T, Chatterjee S, Annaert P, Vander Elst I, Windmolders P, Trebicka J, Nevens F, Laleman W.
Am J Pathol · research support, non-u.s. gov't; journal article · DOI 10.1016/j.ajpath.2014.10.009Efficacy of obeticholic acid in patients with primary biliary cirrhosis and inadequate response to ursodeoxycholic acid.
Hirschfield GM, Mason A, Luketic V, Lindor K, Gordon SC, Mayo M, Kowdley KV, Vincent C, Bodhenheimer HC, Parés A, Trauner M, Marschall HU, Adorini L, Sciacca C, Beecher-Jones T, Castelloe E, Böhm O, Shapiro D.
Gastroenterology · video-audio media; research support, non-u.s. gov't; randomized controlled trial; journal article · DOI 10.1053/j.gastro.2014.12.005NAFLD: obeticholic acid for the treatment of fatty liver disease--NASH no more?
Ray K.
Nat Rev Gastroenterol Hepatol · journal article · DOI 10.1038/nrgastro.2014.203Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial.
Neuschwander-Tetri BA, Loomba R, Sanyal AJ, Lavine JE, Van Natta ML, Abdelmalek MF, Chalasani N, Dasarathy S, Diehl AM, Hameed B, Kowdley KV, McCullough A, Terrault N, Clark JM, Tonascia J, Brunt EM, Kleiner DE, Doo E, NASH Clinical Research Network.
Lancet · article-commentary; research support, n.i.h., intramural; research support, non-u.s. gov't; multicenter study; randomized controlled trial; journal article; research support, n.i.h., extramural · DOI 10.1016/s0140-6736(14)61933-4The response of patients with bile acid diarrhoea to the farnesoid X receptor agonist obeticholic acid.
Walters JR, Johnston IM, Nolan JD, Vassie C, Pruzanski ME, Shapiro DA.
Aliment Pharmacol Ther · clinical trial; research support, non-u.s. gov't; journal article · DOI 10.1111/apt.12999Obeticholic acid, a Farensoid-X receptor agonist, improves portal hypertension by two distinct pathways in cirrhotic rats.
Mookerjee R, Mehta G, Jalan R.
Hepatology · letter; comment · DOI 10.1002/hep.27123Obeticholic acid and budesonide for the treatment of primary biliary cirrhosis.
Silveira MG, Lindor KD.
Expert Opin Pharmacother · review; journal article · DOI 10.1517/14656566.2014.873404FXR agonist INT-747 upregulates DDAH expression and enhances insulin sensitivity in high-salt fed Dahl rats.
Ghebremariam YT, Yamada K, Lee JC, Johnson CL, Atzler D, Anderssohn M, Agrawal R, Higgins JP, Patterson AJ, Böger RH, Cooke JP.
PLoS One · research support, non-u.s. gov't; research-article; journal article; research support, n.i.h., extramural · DOI 10.1371/journal.pone.0060653Testosterone and farnesoid X receptor agonist INT-747 counteract high fat diet-induced bladder alterations in a rabbit model of metabolic syndrome.
Morelli A, Comeglio P, Filippi S, Sarchielli E, Cellai I, Vignozzi L, Yehiely-Cohen R, Maneschi E, Gacci M, Carini M, Adorini L, Vannelli GB, Maggi M.
J Steroid Biochem Mol Biol · research support, non-u.s. gov't; journal article · DOI 10.1016/j.jsbmb.2012.02.007